IQA is a casein kinase 2 (CK2) inhibitor (IC50 = 0.39 µM).1 IQA is selective for CK2 over protein kinase A (PKA), glycogen synthase kinase 3β (GSK3β), lymphocyte cell-specific protein tyrosine kinase (LCK), dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), and PI3Kγ (IC50s = 16, 14, 11, 8, and >200 µM, respectively). IQA decreases the viability of Jurkat leukemia cells in a concentration-dependent manner.2
1.Sarno, S., De Moliner, E., Ruzzene, M., et al.Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA)Biochem. J.374639-646(2003) 2.Sarno, S., Ruzzene, M., Frascella, P., et al.Development and exploitation of CK2 inhibitorsMol. Cell. Biochem.274(1-2)69-76(2005)